<DOC>
	<DOCNO>NCT02216123</DOCNO>
	<brief_summary>This prospective , double-blind , double-dummy , multicenter , comparative study . A total 300 subject randomized treatment Day 1 , minimum 50 female subject must enrol display moderate glucose-6-phosphate dehydrogenase ( G6PD ) deficiency ( &gt; =40 % - &lt; 70 % site median G6PD value ) . Subjects must blood smear positive P. vivax entry . Subjects randomize 2:1 receive tafenoquine ( TQ ) /chloroquine ( CQ ) active comparator primaquine ( PQ ) /CQ . All subject receive CQ Days 1 3 , follow TQ PQ match placebo begin Day 1 2 . Tafenoquine , match placebo , give single , 300mg dose . Subjects receive PQ ( 15mg daily ) match placebo 14 day . The duration study 180 day , include screen randomization treatment ( Day 1 ) , three in-hospital day ( Days 1-3 ) , four out-patient visit treatment study medication ( Days 5 , 8 , 11 15 ) seven follow-up visit ( Days 22 , 29 , 60 , 90 , 120 , 150 180 ) . The primary safety data collect study help understand hemolysis risk G6PD-normal G6PD-deficient subject . The efficacy data produce study support result sister study TAF112582 , pivotal phase III efficacy safety study TQ program .</brief_summary>
	<brief_title>Study Assess Incidence Hemolysis , Safety , Efficacy Tafenoquine ( SB-252263 , WR238605 ) Versus Primaquine Subjects With Plasmodium Vivax Malaria</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Hemolysis</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>A female eligible enter participate study nonpregnant , nonlactating : a. Nonchildbearing potential define : postmenopausal ( 12 month spontaneous amenorrhea &lt; 6 month spontaneous amenorrhea serum folliclestimulating hormone &gt; 40 milliInternational unit per milliliter [ mIU/mL ] ) , premenopausal hysterectomy bilateral oophorectomy ( removal ovary ) bilateral tubal ligation , negative pregnancy test , b. Childbearing potential , negative pregnancy test screening , agree comply one follow treatment stage study period 90 day stop study medication : Use oral contraceptive , either combined progestogen alone used conjunction double barrier method define . Use intrauterine device document failure rate &lt; 1 % per year ; Use depo provera injection ; Double barrier method consist spermicide either condom diaphragm ; Male partner sterile prior female subject 's entry study sole sexual partner female . Complete abstinence intercourse 2 week prior administration study medication , throughout study period 90 day stop study medication . The subject glucose 6phosphate dehydrogenase ( G6PD ) value ( measure quantitative spectrophotometric phenotype assay ) follow : Female subject must enzyme level &gt; = 40 percent site median value G6PD normal male . Male subject must enzyme level &gt; = 70 percent site median value G6PD normal male . The subject screening hemoglobin ( Hb ) value follow : Any subject G6PD value &gt; =70 percent site median value must screen Hb value &gt; =7 g/dL ; Female subject G6PD value &gt; =40 &lt; 70 percent site median value must screen Hb value &gt; =8 g/dL . The subject QT duration correct heart rate Fridericia 's Formula ( QTcF ) &lt; 450 milisecond ( msec ) . Reading base average triplicate Electrocardiograms ( ECGs ) obtain brief recording period machine manual overread . The subject positive malarial smear P. vivax . The subject parasite density &gt; 100 &lt; 100,000 per microliter ( Î¼L ) . Male female subject age 16 year old ( 18 year old Ethiopia ) time sign informed consent . The subject agree G6PD genotyping . The subject willing able comply study protocol . The subject parent/legal guardian , applicable , give write inform , dated consent ; subject give write assent , applicable , participate study . The subject mixed malaria infection ( identify malarial smear rapid diagnostic test ) . The subject severe P. vivax malaria define World Health Organization ( WHO ) criterion . The subject history allergy chloroquine , mefloquine , tafenoquine , primaquine , 4 8aminoquinoline . The subject liver alanine aminotransferase ( ALT ) &gt; 2 x upper limit normal ( ULN ) . The subject severe vomiting ( food inability take food previous 8 hour ) . The subject clinically significant concurrent illness ( e.g. , pneumonia , septicemia ) , preexist condition ( e.g. , renal disease , malignancy ) , condition may affect absorption study medication ( e.g. , vomit , severe diarrhea ) , clinical sign symptom severe cardiovascular disease ( e.g. , uncontrolled congestive heart failure , severe coronary artery disease ) . The subject history porphyria , psoriasis , epilepsy . The subject history significant ocular disease ( e.g . surgery globe , glaucoma , diabetic retinopathy ) evidence corneal retinal abnormality identify clinical screen ophthalmologic examination . The subject take antimalarial ( e.g. , artemisininbased combination therapy , mefloquine , primaquine , 4 8aminoquinoline ) within 30 day prior study entry . The subject take likely require study use medication follow class : Histamine2 blocker antacid ; Drugs hemolytic potential ; Drugs know prolong QTcF interval ; The biguanides phenformin buformin ( exclude metformin ) ; Drugs substrates renal transporter OCT2 , MATE1 AND MATE2K narrow therapeutic index ( example , antiarrhythmic agent dofetilide , procainamide pilsicainide ) The subject receive treatment investigational drug within 30 day study entry , within 5 halflives , whichever longer . The subject recent history illicit drug abuse heavy alcohol intake , full participation study could compromise .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Tafenoquine</keyword>
	<keyword>Plasmodium vivax</keyword>
	<keyword>Hemolysis</keyword>
	<keyword>Primaquine</keyword>
	<keyword>Chloroquine</keyword>
	<keyword>Glucose-6-phosphate dehydrogenase ( G6PD )</keyword>
	<keyword>Relapse</keyword>
</DOC>